Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) – Pipeline Review, H2 2017’, provides in depth analysis on Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Central Nervous System, Hematological Disorders, Respiratory, Cardiovascular and Ophthalmology under development targeting Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Aclaris Therapeutics Inc

Astellas Pharma Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Chipscreen Biosciences Ltd

CJ HealthCare Corp

Concert Pharmaceuticals Inc

Eli Lilly and Co

Galapagos NV

Incyte Corp

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

Nissan Chemical Industries Ltd

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Theravance Biopharma Inc

Vectura Group Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Overview 9

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Therapeutics Development 10

Products under Development by Stage of Development 10

Products under Development by Therapy Area 11

Products under Development by Indication 12

Products under Development by Companies 18

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Therapeutics Assessment 27

Assessment by Mechanism of Action 27

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Companies Involved in Therapeutics Development 31

AbbVie Inc 31

Aclaris Therapeutics Inc 32

Astellas Pharma Inc 32

AstraZeneca Plc 32

Bristol-Myers Squibb Co 33

Chipscreen Biosciences Ltd 33

CJ HealthCare Corp 34

Concert Pharmaceuticals Inc 34

Eli Lilly and Co 35

Galapagos NV 35

Incyte Corp 36

Japan Tobacco Inc 38

Jiangsu Hengrui Medicine Co Ltd 39

Nissan Chemical Industries Ltd 39

Pfizer Inc 40

Portola Pharmaceuticals Inc 40

Sareum Holdings Plc 41

Theravance Biopharma Inc 42

Vectura Group Plc 42

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Drug Profiles 44

ABBV-599 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

ATI-50001 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

ATI-50002 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

AZD-0449 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

AZD-1480 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

AZD-4205 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

baricitinib - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

cerdulatinib - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

CJ-15314 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

CS-944X - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

CTP-543 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

filgotinib - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

INCB-52793 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

itacitinib adipate - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

JTE-052 - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

NIP-565 - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

peficitinib hydrobromide - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

PF-04965842 - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

PF-06700841 - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

ruxolitinib phosphate - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

SAR-20347 - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

SART-29 - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

SHR-0302 - Drug Profile 120

Product Description 120

Mechanism Of Action 120

R&D Progress 120

Small Molecules to Inhibit JAK1 and JAK3 for Autoimmune Diseases and Inflammation - Drug Profile 121

Product Description 121

Mechanism Of Action 121

R&D Progress 121

Small Molecules to Inhibit Jak1 for Oncology - Drug Profile 122

Product Description 122

Mechanism Of Action 122

R&D Progress 122

TD-1473 - Drug Profile 123

Product Description 123

Mechanism Of Action 123

R&D Progress 123

TD-3504 - Drug Profile 125

Product Description 125

Mechanism Of Action 125

R&D Progress 125

upadacitinib tartrate - Drug Profile 126

Product Description 126

Mechanism Of Action 126

R&D Progress 126

VR-588 - Drug Profile 132

Product Description 132

Mechanism Of Action 132

R&D Progress 132

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Dormant Products 133

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Discontinued Products 135

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Product Development Milestones 137

Featured News & Press Releases 137

Oct 30, 2017: Lilly to Present New Data on its Anti-inflammatory Drug Candidate Baricitinib at ACR/ARHP Annual Meeting 137

Oct 24, 2017: AbbVie to Showcase New Data on Upadacitinib at the 2017 ACR/ARHP Annual Meeting 141

Oct 19, 2017: Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent 142

Sep 14, 2017: Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis 142

Sep 11, 2017: Lilly to Present New Data for Olumiant (baricitinib) at the European Academy of Dermatology and Venereology (EADV) Annual Congress 143

Sep 11, 2017: Olumiant is accepted for restricted use within NHS Scotland 143

Sep 11, 2017: AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis 144

Sep 07, 2017: AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis 145

Aug 30, 2017: Lilly To File Baricitinib Resubmission To U.S. FDA Before End Of January 2018 147

Aug 08, 2017: Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis 147

Aug 02, 2017: Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata 148

Jul 25, 2017: Lilly And Incyte Provide Update On Baricitinib 149

Jul 20, 2017: Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease 149

Jul 10, 2017: FDA Lifts Clinical Hold on Concert Pharmaceuticals Clinical Trial with CTP-543 150

Jul 05, 2017: Galapagos: New Phase 2 study with filgotinib in non-infectious uveitis 150

Appendix 151

Methodology 151

Coverage 151

Secondary Research 151

Primary Research 151

Expert Panel Validation 151

Contact Us 151

Disclaimer 152

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 10

Number of Products under Development by Therapy Areas, H2 2017 11

Number of Products under Development by Indications, H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 16

Number of Products under Development by Indications, H2 2017 (Contd..4), H2 2017 17

Number of Products under Development by Companies, H2 2017 18

Products under Development by Companies, H2 2017 19

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 20

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 21

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 22

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 23

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 24

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 25

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 26

Number of Products by Stage and Mechanism of Actions, H2 2017 27

Number of Products by Stage and Route of Administration, H2 2017 29

Number of Products by Stage and Molecule Type, H2 2017 30

Pipeline by AbbVie Inc, H2 2017 31

Pipeline by Aclaris Therapeutics Inc, H2 2017 32

Pipeline by Astellas Pharma Inc, H2 2017 32

Pipeline by AstraZeneca Plc, H2 2017 33

Pipeline by Bristol-Myers Squibb Co, H2 2017 33

Pipeline by Chipscreen Biosciences Ltd, H2 2017 34

Pipeline by CJ HealthCare Corp, H2 2017 34

Pipeline by Concert Pharmaceuticals Inc, H2 2017 35

Pipeline by Eli Lilly and Co, H2 2017 35

Pipeline by Galapagos NV, H2 2017 36

Pipeline by Incyte Corp, H2 2017 37

Pipeline by Japan Tobacco Inc, H2 2017 39

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 39

Pipeline by Nissan Chemical Industries Ltd, H2 2017 40

Pipeline by Pfizer Inc, H2 2017 40

Pipeline by Portola Pharmaceuticals Inc, H2 2017 41

Pipeline by Sareum Holdings Plc, H2 2017 42

Pipeline by Theravance Biopharma Inc, H2 2017 42

Pipeline by Vectura Group Plc, H2 2017 43

Dormant Products, H2 2017 133

Dormant Products, H2 2017 (Contd..1), H2 2017 134

Discontinued Products, H2 2017 135

Discontinued Products, H2 2017 (Contd..1), H2 2017 136

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 10

Number of Products under Development by Therapy Areas, H2 2017 11

Number of Products under Development by Top 10 Indications, H2 2017 12

Number of Products by Stage and Mechanism of Actions, H2 2017 27

Number of Products by Routes of Administration, H2 2017 28

Number of Products by Stage and Routes of Administration, H2 2017 28

Number of Products by Stage and Molecule Type, H2 2017 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports